Sparsentan for proteinuria from VEGF inhibitor cancer treatment
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests if sparsentan can reduce high levels of protein in the urine caused by VEGF signaling pathway inhibitors (VSPIs), a type of cancer treatment. It may help protect kidney function during cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have active cancer
- You are currently taking a VEGF inhibitor (VSPI) and have new high protein in your urine (2+ on a dipstick or higher)
- Your kidney function (eGFR) is 45 mL/min or above
- You have not had high protein in your urine before starting VSPI treatment
- You do not have serious heart disease (like heart failure or recent heart attack/stroke), liver problems, or other conditions on the exclusion list
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
This study documents real-world experiences of patients in Switzerland taking sparsentan, a newer medication for IgA nephropathy (a type of kidney disease caused by immune deposits). The goal is to understand how well sparsentan works and how safe it is when used in everyday clinical practice.
This trial tests if the drug finerenone can help children with IgA vasculitis (HSP nephritis) who have mild protein in their urine. It aims to protect kidney function without using stronger medications like steroids.
This study tests whether survodutide, an injected medication, can lower the amount of protein in your urine—a key sign of kidney damage. It's for people with chronic kidney disease who are already on standard blood pressure medications.
Hear when a new Proteinuric Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.